Volume 3, Issue 2, March 2015, Page: 28-49
Diabetic Foot Ulcer: A Review
Mohammad Zubair, Rajiv Gandhi Centre for Diabetes and Endocrinology, Faculty of Medicine, Aligarh Muslim University, Aligarh 202002, India
Abida Malik, Department of Microbiology, Faculty of Medicine, Aligarh Muslim University, Aligarh, India
Jamal Ahmad, Rajiv Gandhi Centre for Diabetes and Endocrinology, Faculty of Medicine, Aligarh Muslim University, Aligarh 202002, India
Received: Dec. 18, 2014;       Accepted: Dec. 30, 2014;       Published: Feb. 26, 2015
DOI: 10.11648/j.ajim.20150302.11      View  2939      Downloads  335
Abstract
Diabetic foot problems are common throughout the world, resulting in major medical, social and economic consequences for the patients, their families, and society. Foot ulcers are more likely to be of neuropathic origin, and therefore eminently preventable. People at greatest risk of ulceration can easily be identified by careful clinical examination of the feet: education and frequent follow-up. Infection when complicates a foot ulcer, combination can be limb or life-threatening, and infection is defined clinically, but wound cultures assist in identifying the causative pathogens. Tissue specimens are strongly preferred to wound swabs for wound cultures. Antimicrobial therapy should be guided by culture results, and although such therapy may cure the infection, it does not heal the wound. Alleviation of the mechanical load on ulcers (offloading) should always be a part of treatment. Plantar neuropathic ulcers typically heal in 6 weeks with irremovable casting, because pressure at the ulcer site is mitigated and compliance is enforced. The success of other approaches to offloading similarly depends on the patients’ adherence to the effectiveness of pressure relief.
Keywords
Diabetic Foot, India
To cite this article
Mohammad Zubair, Abida Malik, Jamal Ahmad, Diabetic Foot Ulcer: A Review, American Journal of Internal Medicine. Vol. 3, No. 2, 2015, pp. 28-49. doi: 10.11648/j.ajim.20150302.11
Reference
[1]
DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-986.
[2]
United Kingdom Prospective Diabetes Study Group (UKPDS). Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS). Lancet 1998; 352: 837-853.
[3]
King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 1993;16: 157–177.
[4]
Amos AF, McCarty DJ, Zimmet P, The rising global burden of diabetes and its complications: estimates and projections to the year 2010, Diabet Med 1997; 14 (5) S1–S85.
[5]
King H, Aubert R, Herman W. Global burden of diabetes, 1995–2025: prevalence, numerical estimates and projections, Diabetes Care 1998; 21 (9):1414–1431.
[6]
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care 2004; 27 (5): 1047–1053.
[7]
Armstrong DG, Peters EJG, Athanasiou KA, et al. Is there a critical level of planter foot pressure to identify patients at risk for neuropathic foot ulcerations? J Foot Ankle Surg 1998; 37(4):303-307.
[8]
International Diabetes Federation, Diabetes Atlas, 2nd ed., International Diabetes Federation, Brussels, 2003.
[9]
International Diabetes Federation, Diabetes Atlas, 3rd ed., International Diabetes Federation, Brussels, 2006.
[10]
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011; 94(3):311-321.
[11]
Ramachandran A, Snehalatha C, Latha E, et al. Impacts of urbanization on the lifestyle and on the prevalence of diabetes in native Asian Indian population. Diabetes Res Clin Pract 1999; 44: 207–213.
[12]
Ahuja MMS. Epidemiological studies on diabetes mellitus in India. In: Ahuja MMS, editor. Epidemiology of diabetes in developing countries. New Delhi: Interprint 1979; 29-38.
[13]
Ramachandran A, Jali MV, Mohan V, et al. High prevalence of diabetes in an urban population in south India. BMJ 1988; 297: 587-90.
[14]
Sridhar GR, Rao PV, Ahuja MMS. Epidemiology of diabetes and its complications. In: RSSDI textbook of diabetes mellitus. Hyderabad: Research Society for the Study of Diabetes in India 2002: 95-112.
[15]
Rao PV, Ushabala P, Seshaiah V, et al. The Eluru survey: prevalence of known diabetes in a rural Indian population. Diabetes Res Clin Pract 1989; 7 :29-31.
[16]
Zargar AH, Khan AK, Masoodi SR, et al. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in the Kashmir Valley of the Indian subcontinent. Diabetes Res Clin Pract 2000; 47: 135-6.
[17]
Ramachandran A, Snehalatha C, Kapur A, et al. Diabetes Epidemiology Study Group in India (DESI). High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001; 44 :1094-101.
[18]
Gupta A, Gupta R, Sarna M, et al. Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract 2003; 61: 69-76.
[19]
Menon VU, Kumar KV, Gilchrist A, et al. Prevalence of known and undetected diabetes and associated risk factors in central Kerala - ADEPS. Diabetes Res Clin Pract 2006; 74: 289-94.
[20]
Sadikot SM, Nigam A, Das S, et al. The burden of diabetes and impaired fasting glucose in India using the WHO 1999 critetia. Prevalence of diabetes in India study (PODIS). On behalf of Diabetes India, Diabetes Research and Clinical Practice 2004; 66: 301-307.
[21]
Shah JE, Sicree RA, Zimmet P. Global estimation of the prevalence of diabetes for 2010 and 2030. Diab Res Clin Prac 2010; 87(4); 4-14.
[22]
Moss SE, Klein R, Klein B. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch. Intern. Med. 1992; 152: 610-616.
[23]
Walters DP, Gatling W, Mullee MA, et al. The distribution and severity of diabetic foot disease: A community study with comparison to a non-diabetic group. Diabet Med 1992; 9:354-358.
[24]
Palumbo PJ, Melton LJI. Peripheral vascular disease and diabetes. In National Diabetes Data Group(ed): Diabetes In America, 2nd ed (NIH publ. no. 495-1468). Washington, DC, U.S. Government Printing Office. 1995:401-408.
[25]
Oakley W, Caterall CF: Aetiology and management of lesions of the feet in diabetes. Br Med J. 1956; 27:953 -955.
[26]
Shea JD. Pressure sores: classification and management. Clin Orthop 1975; 112 : 89 – 100.
[27]
Wagner FW: The dysvascular foot: a system of diagnosis and treatment. Foot Ankle 1981; 2:64 -122.
[28]
Knighton DR, Ciresi KF, Fiegel VD, et al. Classification and treatment of chronic nonhealing wounds: successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg. 1986; 204: 332–330.
[29]
Kaufman J, Breeding L, Rosenberg N. Anatomical location of acute diabetic foot infection: its influence on the outcome of treatment. Am Surg. 1987; 53:109 -112.
[30]
Jones EW, Peacock I, McLain S, et al. A clinicopathological study of diabetic foot ulcers. Diabet Med. 1987; 4:475 -479.
[31]
Lavery LA, Armstrong DG, Harkless LB: Classification of diabetic foot wounds. J Foot Ankle Surg. 1996; 35: 528-531.
[32]
Apelqvist J, Castenfors J, Larsson J. Wound classification is more important than site of ulceration in the outcome of diabetic foot ulcers. Diabet Med 1989; 6:526-530.
[33]
Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am. J. Surg. 1998; 176(Suppl. 2A):5S–10S.
[34]
Oyibo SO, Jude EB, Tarawneh I, et al. The effect of ulcer size and site, patient’s age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 2001; 18(2):133-138.
[35]
Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers: A pooled analysis. Arch Dermatol 2000; 136(12):1531-1535.
[36]
Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: The association of wound size, wound duration, and wound grade on wound healing. Diabetes Care 2002; 25(10): 835-1839.
[37]
Pecoraro RE, Ahroni J, Boyko EJ, et al. Chronology and determinants of tissue repair in diabetic lower extremity ulcers. Diabetes 1991; 40: 1305-1313.
[38]
McNeely MJ, Bokyo EJ. Diabetes related comorbitidies in Asian Americans: Results of a National Health Survey. J Diabetes Complications 2005; 19(2):101-106.
[39]
Sheehan P, Jones P, Caselli A, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003; 26(6):1879-1882.
[40]
Abbott CA, Vileikyte L, Williamson S, et al. Multicentre study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 2004; 94(5):379–83.
[41]
Boyko EJ, Ahroni JH, Stensel V, et al. A prospective study of risk factors for diabetic foot ulcer: the Seattle Diabetic Foot Study. Diabetes Care. 1999; 22:1036-42.
[42]
Kastenbauer T, Sauseng S, Sokol G, et al. A prospective study of predictors for foot ulcerations in type 2 diabetes. J American Podiat Med Assoc 2001; 91(7):343-350.
[43]
Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: Incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002; 19(5):377-384.
[44]
Kumar S, Ashe HA, Parnell LN, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet. Med. 1994; 11: 480–484.
[45]
Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying diabetic patient at high risk for lower extremity amputation in a primary health care setting: A prospective evaluation of simple screening criteria. Diabetes Care 1992; 15(10):1386-1389.
[46]
Moss SE, Klein R, Klein BE. The 14-year incidence of lower extremity amputations in a diabetic population. The Wisconsin Epidemiolog Study of Diabetic Retinopathy. Diabetes Care 1999; 22(6)951-959.
[47]
Global Lower Extremity Amputation Study Group(GLEASG): Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. Br J Surg 2000; 87(3):328-337..
[48]
Lehto S, Pyorala K, Ronnemaa T, et al. Risk fators predicting lower extremity amputation in NIDDM. Diabetes Care 1996; 19(6):607-612.
[49]
Resnick HE, Valsania P, Phillips CL. Diabetes mellitus and non-traumatic lower extremity amputation in black and white Americans: The national health and nutrition examination survey epidemiological follow-up study, 1971-1992. Arch Intern Med 1999; 159:2470-2475.
[50]
Jeffcoate WJ. The incidence of amputation in diabetes. Acta Chir Beig. 2005; 105: 140-144.
[51]
Adler AI, Boyko EJ, Ahroni J, Smith DG. Lower extremity amputation in diabetes: the independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 1999; 22:1029-1035.
[52]
Reiber GE, Bokyo EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In National Diabetes Data Group (ed): Diabetes in America, 2nd ed (NIH publ. no.95 1468). Washington, DC, U.S. Government Printing Office: 409-428, 1995.
[53]
Tentolouris N, Al-Sabbagh S, Walker MG, et al. Mortality in diabetic and nondiabetic patients after amputations performed from 1990 to 1995: a year follosw up study. Diabetes Care. 2004 ; 27: 1598-1604.
[54]
Nelson RG, Gohdes DM, Everhart JE, et al. Lower extremity amputations in NIDDM: 12-yr follow up study in Pima Indians. Diabetes Care. 1988; 11: 8-16.
[55]
Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus: a case control study. Ann Intern Med 1992; 117: 97–105.
[56]
Selby ZV, Zhang D. Risk factors for lower extremity amputation in persons with diabetes. Diabetes Care 1995; 18(4): 509-516.
[57]
Hamalainen H, Ronnemma T, Halonen JP, et al. Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: A population-based 7 year follow-up study. J Int Med 1999; 246:97-103.
[58]
Selby JV, Karter AJ, Ackerson LM, et al. Developing a prediction rule from automated clinical database to identify high-risk patients in a large population with diabetes. Diabetes Care 2001; 24(9):1547-1555.
[59]
Mayfield JA, Reiber GE, Nelson RG, et al. A foot risk classification system to predict diabetic amputation in Pima Indians. Diabetes Care 1996; 19(7):704-709.
[60]
Hennis AJJ, Fraser HS, Jonnalagadda R, et al. Explainations for the high risk of diabetes-related amputation in a Carribean population of black African descent and potential for prevention. Diabetes Care 2004; 27(11):2636-2641.
[61]
Lee JS, Lu M, Lee VS, et al. Lower extremity amputation . Incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study. Diabetes. 1993; 42: 876-882.
[62]
Resnick HE, Carter EA, Sosenko JM, et al. Incidence of lower extremity amputation in American Indians:The Strong Heart Study. Diabetes Care 2004; 27(8):1885-1891.
[63]
Boulton AJM, Gries FA, Jervell JA. Guidelines for the diagnostic and outpatient management of diabetic peripheral neuropathy. Diabet Med 15:508-514, 1998.
[64]
Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population based cohort: The Rochester Diabetic Neuropathy Study. Neurology.1993; 43:817-824.
[65]
Serra J. Overview of neuropathic pain syndromes. Acta Neurol Scand 1999; 173 (Suppl):7-11.
[66]
Dyck PJ. Detection, characterization and Staging of polyneuropathy: Assessed in Diabetics. Muscle Nerve.1988; 11:21-32.
[67]
Dyck PJ, Karnes J, O’Brien PC. Diagnosis, Staging and classification of diabetic neuropathy and association with other complications. In Dyck PJ. Thomas PK, Asbury AK et al (eds). Diabetic Neuropathy. Philadelphia: WB Saunders. 1987: 36-44.
[68]
American Diabetic Association. Clinical Practice Recommendations 1995. Diabetic Care 18:8-15, 1995.
[69]
Robinson LR, Stolov WC, Rubner DE, et al. Height is an independent risk factor for neuropathy in diabetic men. Diabetes Res Clin Pract 1992; 16:97-102.
[70]
Thomas PK. Metabolic neuropathy. J R Coll Physicians Lond 1973; 7:154-160.
[71]
Polydefkis M, Griffin JW, Mcarthur J. New insights into diabetic polyneuropathy. JAMA 2003; 290(10):1371-1376.
[72]
Haslbeck KM, Schleicher E, Bierhaus A et al. The AGE/RAGE/NF-(kappa) B pathwaymay contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113(5):288-291.
[73]
Cameron NE, CottorMA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46(suppl 2):S31-S37.
[74]
Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retina ischemia in pigs by PKC beta inhibition with LY333531. Ophthalmol Vis Sci.1998; 39: 171-179.
[75]
Hata Y, Rook SL, Aiello LP. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependant pathway. Diabetes 1999; 48: 1145-1155.
[76]
Cameron NE, Cotter MA. Comparison of the effects of ascorbyl µ-linolenic acid and µ-linolenic acid in the correction of neurovascular deficits in diabetic rats. Diabetilogica 1996; 39:1047-1054.
[77]
Cameron NE, Cotter MA. Basso M, et al. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetilogica 1997; 40:271-281.
[78]
Yorek MA, Wiese TJ, Davidson EP, et al. Reduced motor nerve conduction velocity and Na(+)-K(+)-ATPase activity in rats maintained on L-fructose diet. Reversal by myo-inositol supplementation. Diabetes 1993; 42:1401-1406.
[79]
Honing ML, Morrison PJ, Banga JD, et al. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 14:241-249, 1998.
[80]
Canal N, Nemni R. Autoimmunity and diabetic neuropathy. Clin Neurosci 1997; 4:371-373.
[81]
Brownlee M. Biochemistry and Molecular cell biology of diabetic complications. Nature. 2001; 414: 813-820.
[82]
Maillard LC. Action des acides amines sur les sucres: formation des melaniodines par voie methodique. C.R. Academy Sciences. 1912; 154: 66–68.
[83]
Brownlee M, Aiello LP, Friedman E, Vinik AI, Nesto RW, Boulton AJM. Complications of Diabetes Mellitus. In: Williams Textboot of Endocrinology. 10th ed. 2003 (eds) Larsen R, Krokenberg HM, Melmed S, Polonsky KS. Suunders pp 1560-1563.
[84]
Pfeifer MA, Ross D, Schrange J, et al. A highly successful and novel model for the treatment of chronic painful peripheral neuropathy. Diabetes Care 1993; 16:1103-1115.
[85]
Sharma KR, Cross J, Farronay O, et al. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002; 59:758-765.
[86]
Beach KW, Bedford GR, Bergelin RO, et al. Progression of lower-extremity arterial occlusive disease in type 2 diabetes mellitus. Diabetes Care 1998; 11:464–472.
[87]
Uusitupa MI, Niskanen LK, Siitonen O, et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990; 82:27–36.
[88]
Gadepalli R, Dhawan B, Sreenivas V, et al. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care. 2006; 29:1727-1732
[89]
Zubair M, Malik A, Ahmad J. Study of Plasmid mediated Extended Spectrum Beta Lactamase producing Strains of Enterobacteriaceae, Isolated from Foot Infections in North Indian tertiary care hospital. Diabetes Technology and Therapeutics 2012: 12(4); 315-324.
[90]
Premlatha G, Shanthirani S, Deepa R, et al. Prevalence and risk factors of peripheral vascular disease in a selected South Indian populations. Diabetes Care 2000; 23(9): 1295-1300.
[91]
Weerasuriya N, Siribaddana S, Dissanayake A, et al. Long-term complications in newly diagnosed Sri Lankan patients with type 2 diabetes mellitus. QJM 1998; 91:439–443.
[92]
Melton LJ, Macken KM, Palumbo PJ, et al. Incidence and prevalence of clinical peripheral vascular disease in a population based cohort of diabetic patients. Diabetes Care 1980; 3:650–654.
[93]
Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study. Diabetologia. 1995; 38:86 –96.
[94]
Federman DG, Trent JT, Froelich CW, et al. Epidemiology of peripheral vascular disease: a predictor of systemic vascular disease. Ostomy Wound Manage 1998; 44:58–62.
[95]
Cheng SW, Ting AC, Lau H, et al. Epidemiology of atherosclerotic peripheral arterial occlusive disease in Hong Kong. World J Surg 1999; 23:202–206.
[96]
Papademetriou V, Narayan P, Rubins H, et al. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high density lipoprotein cholesterol levels and desirable low density lipoprotein cholesterol levels: Department of Veterans Affairs HDL Intervention Trial. Am Heart J 1998; 136:734–740.
[97]
Katsilambros NL, Tsapogas PC, Arvanitis MP, et al. Risk factors for lower-extremity arterial disease in non-insulin-dependent diabetic persons. Diabet Med 1996; 13:243–246.
[98]
Jager A, Kostense PJ, Ruhe HG, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19:617– 624.
[99]
Taylor LM Jr, Moneta GL, Sexton GJ, et al. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999; 29:8–19.
[100]
Wollesen F, Dahlen G, Berglund L, et al. Peripheral atherosclerosis and serum lipoprotein (a) in diabetes. Diabetes Care 1999; 22:93–98.
[101]
Kannel WB, D’Agostino RB, Wilson PW, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672–676.
[102]
Edmonds ME, Blundell MP, Morris ME, et al. Improved survival of the diabetic foot: The role of a specialized foot clinic. Q J Med. 1986; 60(232):763-771.
[103]
Veves A, Murray H, Young MJ, et al. Do high foot pressures lead to foot ulcerations?: A prospective study [abstract]. Diabetologia 1991; 34(2):A40.
[104]
Stess RM, Jensen SR, Mirmiran R. The role of dynamic planter pressures in diabetic foot ulcers. Diabetes Care 1997; 20(5):855-858.
[105]
Murray HJ, Young MJ, Hollis S, et al. The association between callus formation, high pressures and neuropathy in diabetic foot ulceration. Diabet Med 1996; 13 (11):979-982.
[106]
Delbridge L, Ellis CS, Robertson K, et al. Nonenzymatic glycosylation of keratin from the stratum corneum of the diabetic foot. British Journal of Dermatology. 1985; 112: 547-554.
[107]
Birke IA, Cornwall MW, Jackson M. Relationship between hallux limitus and ulceration of the great toe. Journal of Orthopaedic and Sports Physical Therapy. 1988; 10: 172-176.
[108]
Fernando DJS, Masson EA, Veves A, et al. Relationship of limited joint mobility to abnormal foot pressures and diabetic foot ulceration. Diabetes Care. 1991; 14: 8-11.
[109]
Hampton G, Birke IA. Treatment of wounds caused by pressure and insensitivity. In: Kloth LC, MeCulloch iM, Feeder iA (eds). Wound healing: alternatives in management. Davis, Philadelphia 1990: 196-220.
[110]
Boyko EJ, Lipsky BA. Infection and diabetes mellitus. In Harris MI (ed): Diabetes in America, 2nd edition. NIH publication No 95-1468. Bethesda, MD: National Institute of Health. 1995, pp 485-499.
[111]
Muller LM, Gorter KJ, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41(3): 281-288.
[112]
Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26 (2): 510-513.
[113]
Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot?. Diabetes Metab. Res. Rev 2000;16:S75–S83.
[114]
Anandi C, Alaguraja D, Natarajan V, Ramanathan M, Subramaniam CS, Thulasiram M, Sumithra S. Bacteriology of diabetic foot lesions. Indian Journal of Medical Microbiology 2004; 22(3): 175-178.
[115]
Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers and amputation. Wound Repair Regen. 2005; 13: 230–236.
[116]
Lavery LA, Armstrong DG, Wunderlich RP, et al. Risk factors for foot infection in person with diabetes. Diabetes Care 2006; 6: 1288-1293.
[117]
Peters EJ, Lavery LA, et al. Diabetic lower extremity infection: Influence of physical, psychological, and social factors. J Diabetes Complications 2005; 19 (2): 107-112.
[118]
Pendsey S: Epidemiological aspects of diabetic foot. J Diabetes Develop Countries 1994; 2: 37-38.
[119]
Viswanathan V, Jasmine JJ, Snehalatha C, et al. Prevalence of pathogens in diabetic foot infection in south Indian type 2 diabetic patients. JAPI 2002; 50:1013-1016.
[120]
Zubair M, Malik A, Ahmad J. Clinico-microbiological study and antimicrobial drug resistance profile of diabetic foot infections in North India. The Foot 2011 (March): 21(1): 6-14.
[121]
Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann Med 2002, 34(6): 419-427.
[122]
Andrew S. Powlson and Anthony PC. The treatment of diabetic foot infections. J Antimicrob Chemother 2010; 65 (3): 3–9.
[123]
Citron DM, Goldstein EJC, Merriam CV, Lipsky BA, Abtamson MA. Bacteriology of moderate-to-severe Diabetic foot infections and in vitro activity of antimicrobial agents. J. Clin Microbio 2006; 45(9):2819-2829.
[124]
Ramakant P, Verma AK, Misra R, Prasad KN, Chand G, Mishra A, Agarwal G, Agarwal A, Mishra AK. Changing microbiological profile of pathologenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose?. Diabetologia 2011; 54:58-64.
[125]
Zubair M, Malik A, Ahmad J. The impact of creatinine clearance on the outcome of diabetic foot ulcers in North Indian tertiary care Hospital. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2011; 5(3): 120-125.
[126]
Louie TJ, Bartlett JG, Tally FP, Gorbach SL. Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann Intern Med. 1976; 85:461-463.
[127]
Sapico FL, Witte JL, Canawati HN, et al. The infected foot of the diabetic patient: quantitative microbiology Guidelines for Diabetic Foot Infections • CID 2004:39 (1 October) 905 and analysis of clinical features. Rev Infect Dis. 1984; 6(Suppl 1): S171 6.
[128]
Lily SYN, Kwang LL, Yeow SCS, Tan TY. Anaerobic culture of diabetic foot infections: organisms and aantimicrobial susceptibilities. Ann Acad Med Singapore 2008; 37:936-939.
[129]
Sapico FL, Canawati HN, Witte JL, et al. Quantitative aerobic and anaerobic bacteriology of infected diabetic feet. J Clin Microbiol. 1980; 12:413–20.
[130]
Cooper CR Jr, McGinnis MR,. Arch. Pathol. Lab. Med 1997; 121, 798-804.
[131]
Abdulrazak A, Bitar ZI, Al-Shamali AA, and Mobasher LA. Bacteriological study of diabetic foot infections. J. Diabetes Complications 2005; 19:138-141.
[132]
Raja NS. Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. J Microbiol Immuno Infect 2007; 40(1):39-44
[133]
Armstrong DG, Joseph WS, Lavery L, et al. Treating MRSA infections. Experts share their insights on diagnosis and treatment. Wounds 2004; S1–S23.
[134]
Bridges RM, Deitch EA. Diabetic foot infections: Pathophysiology and treatment. Surg Clin North Am 1994, 74: 537-555.
[135]
Bendy RH, Nuccio PA, Wolfe E, et al. Relationship of quantitative wound bacterial counts to healing of decubiti. Effect of topical gentamicin. Antimicrobial Agents and Chemotherapy 1964; 4, 147–55.
[136]
American Diabetes Association. Consensus development conference on diabetic foot wound care. Diabetes Care 1999; 22, 1354–60.
[137]
Gardner SE, Frantz RA & Doebbeling BN. The validity of the clinical signs and symptoms used to identify localized chronic wound infection. Wound Repair and Regeneration. 2001; 9: 178–86.
[138]
Tice A, Hoaglund P, Giani G, et al. Outcomrs of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003; 114(9): 723-728.
[139]
Lipsky BA, McDonald D, Litka PA. Treatment of infected diabetic foot ulcers: Topical MSI-78 vs. oral ofloxacin (abstract) Diabetologia 1997; 40(1): 482.
[140]
Raymakers JT, Houben AJ, et al. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabetic Medicine 2001; 18(3): 229-234.
[141]
Armstrong DG, Stephan KT, Joseph, et al. What is the shelf –life of physician- mixed antibiotic-impregnated calcium sulphate pellets? J Foot Ankle Surg 2003, 42(5): 302-304.
[142]
Lipsky BA, Pecoraro RE, Larson SA, et al. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch. Intern. Med. 1990; 150: 790-797.
[143]
Van Damme H, Rorive M, Lavery LA, et al. Amputations in diabetic patients: A plea for footsparing surgery. Acta chir Belg 2001; 101(3): 123-129.
[144]
Rauwerda JA. Surgical treatrment of the infected diabetic foot. Diabetes Metab Rs Rev2004, 20(1): S41-S44.
[145]
Tan JS, Friedman NM, Hazelton-Miller C, et al. Can aggressive treatment of diabetic foot infection reduce the need for above-ankle amputation? Clin Infect Dis 1996; 23: 286-291.
[146]
Abbott CA, Boyko EJ. Diabetes related comorbidities in Asian Americans: results of a national health Survey. J Diabetes Complications 19(2); 101-106: 2005.
[147]
Centres for Disease Control and Prevention: History of foot ulcer among persons with diabetes: United States, 2000-2002, MMWR Morb Mortal Wkly Rep 2003; 52(45):1098-1103,.
[148]
Muller IS, De Grauw WJ, Van Gerwen WH, et al. Foot ulceration and lower limb amputation in type 2 diabetic patients in Dutuch primary health care. Diabetes Care 2002; 25(3):570-574.
[149]
Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetics Care 1999; 22:382-387.
[150]
Abbott CA, Vileikyte L, Williamson S, et al., Multicentric study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes care 1998; 21: 1071-1075.
[151]
Boyko EJ, Ahroni JH, Cohen V, et al., Prediction of diabetic foot occurance using commonly available clinical information: The Seattle Diabetic Foot Study. Diabetes Care 2006; 29(6): 1202-1207.
[152]
Carrington AL, Shaw JE, Van Schie CH, et al. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care 25(11):2010-2015, 2002.
[153]
Litzelaman DK, Slemenda CW, Langefeld CD, et al. Reduction of lower extremity clinical abnormalities in patients with non-insulin dependant diabetes mellitus: A randomized, controlled trial. Ann Intern Med 1993; 19(1): 36-41.
[154]
Chaturvedi N, Stevens LK, Fuller JH, et al. Risk factors, ethnic difference and mortality associated with lower extremity gangrene and amputation in diabetes. Diabetiologica 2001; 44(suppl 2):S65-S71.
[155]
Humphrey ARG, Dowse GK, Thomas K, et al. Diabetes and nontraumatic lower extremity amputations: incidence, risk factors and prevention: 12-year follow- up study in Nauru. Diabetes Care. 1996; 19:710–714.
[156]
Humphrey LL, Palumbo PJ, Butters MA, et al. The contribution of non-insulin dependent diabetes to lower extremity amputation in the community . Arch. Intern. Med.1994; 154:885-892.
[157]
Lehto S, Pyorala K, Ronnemaa T, et al. Risk fators predicting lower extremity amputation in NIDDM. Diabetes Care 1996; 19(6):607-612.
[158]
Morris AD, McAlpine R, Steinke D, et al. Diabetes and lower limb amputation in the community. Diabetes Care 1998; 21:738-743.
[159]
Siitonen OL, Niskanen LK, Laakso M, et al. Lower extremity amputation in diabetic and nondiabetic patients. Diabetes Care 1993; 16:16-20.
[160]
Trautner C, Hasstert B, Giani G, et al. Incidence of lower limb amputations and diabetes. Diabetes Care 1996; 19(9): 1006-1009.
[161]
Van Houtum W, Lavery LA. Outcomes associated with diabetes-related amputations in the Netherlands and in the state of California. J Int Med 1996; 240:227-231.
[162]
Hennis AJJ, Fraser HS, Jonnalagadda R, et al. Explanations for the high risk of diabetes-related amputation in a Carribean population of black African descent and potential for prevention. Diabetes Care 2004; 27(11):2636-2641.
Browse journals by subject